|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XE34
|
|
gptkbp:brand
|
gptkb:Lorbrena
|
|
gptkbp:casnumber
|
1251058-33-0
|
|
gptkbp:chemical_formula
|
C22 H24 Cl2 N4 O2 S
|
|
gptkbp:clinical_trial
|
improved progression-free survival
overall response rate
Phase 1/2
ALK-positive metastatic non-small cell lung cancer
|
|
gptkbp:developed_by
|
gptkb:Pfizer
|
|
gptkbp:dissolved
|
soluble in DMSO
|
|
gptkbp:dosage_form
|
100 mg once daily
|
|
gptkbp:drug_interactions
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:effective_date
|
2018-11-02
|
|
gptkbp:excretion
|
biliary and fecal
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lorlatinib
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_compared_to
|
gptkb:brigatinib
gptkb:alectinib
gptkb:ceritinib
gptkb:crizotinib
|
|
gptkbp:is_monitored_by
|
required for blood glucose levels
required for cardiac function
required for liver function
required for vision changes
|
|
gptkbp:lifespan
|
about 24 hours
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
inhibitor of ALK and ROS1 tyrosine kinases
|
|
gptkbp:metabolism
|
primarily hepatic
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmacokinetics
|
high oral bioavailability
inhibits tumor growth
|
|
gptkbp:provides_guidance_on
|
included in NCCN guidelines
|
|
gptkbp:research
|
ongoing for combination therapies
|
|
gptkbp:research_focus
|
ALK resistance mutations
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
weight gain
peripheral neuropathy
hyperglycemia
visual disturbances
pneumonitis
elevated liver enzymes
cardiac issues
|
|
gptkbp:storage
|
store at room temperature
|
|
gptkbp:targets
|
gptkb:ALK_gene_rearrangements
|
|
gptkbp:treatment
|
longer duration of response
|
|
gptkbp:type_of_care
|
important for treatment efficacy
|
|
gptkbp:used_for
|
treatment of non-small cell lung cancer
|
|
gptkbp:weight
|
461.42 g/mol
|
|
gptkbp:bfsParent
|
gptkb:ALK_gene_rearrangements
gptkb:Lorbrena
gptkb:JAK1
gptkb:anaplastic_large_cell_lymphoma,_ALK-positive
gptkb:anaplastic_lymphoma_kinase_protein
|
|
gptkbp:bfsLayer
|
7
|